Colon cancer proves tougher target for Amgen's KRAS drug

Amgen caught the cancer field's attention this summer with early results showing one of its drugs can shrink lung tumors driven to growth by a commonly mutated gene.

But replicating that efficacy in colon cancer may be more difficult, according to new data set to be presented Saturday at the European Society of Medical Oncology's annual meeting in Barcelona, Spain.